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Purpose: To study the effect of smoking on the prevalence of recurrent aphthous stomatitis 
(RAS) and to examine whether intensity and duration of smoking influence RAS lesions.
Subjects and methods: A cross-sectional survey was conducted on a random sample of 
1000 students of The University of Jordan, Amman, between May and September 2008. 
Sociodemographic factors and details about smoking habits and RAS in last 12 months were 
collected.
Results: Annual prevalence (AP) of RAS was 37.1%. Tobacco use was common among 
students: 30.2% were current smokers and 2.8% were exsmokers. AP was not significantly 
influenced by students’ age, gender, marital status, college, and household income but was 
significantly affected by place of living (P = 0.02) and presence of chronic diseases (P = 0.03). 
No significant difference in AP of RAS was found between smokers and nonsmokers. Cigarette 
smokers who smoked heavily and for a longer period of time had significantly less AP of RAS 
when compared to moderate smokers and those who smoked for a shorter period of time. 
The protective effect of smoking was only noticed when there was heavy cigarette smoking 
(.20 cigarettes/day) (P = 0.021) or smoking for long periods of time (.5 years) (P = 0.009). 
Nevertheless, no significant associations were found between intensity or duration of smoking 
and clinical severity of RAS lesions.
Conclusion: The “protective effect” of smoking on RAS was dose- and time-dependent. When 
lesions are present, smoking had no effect on RAS severity.
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Introduction
Recurrent aphthous stomatitis (RAS) is a common oral mucosal disease that typically 
starts in childhood as recurrent, usually painful, small ulcers that can be single or 
multiple. Its prevalence rate ranges from 5%–60%.1 RAS is of unknown etiology; 
precipitated factors include stress, physical or chemical trauma, food sensitivity, 
and genetic predisposition.1,2 Persons with RAS may have alteration of local cell-
mediated immunity.1 The lesions can be associated in some individuals with systemic 
conditions such as Behçet’s disease, gastrointestinal disease, or immune defects such 
as HIV/AIDS.3 The still unclear etiology has resulted in treatments that are largely 
empiric and aimed at symptom reduction.
Although the mechanism is not yet fully understood, investigators have noticed 
lower prevalence rate of RAS in smokers when compared to nonsmokers,4–8 increase in 
the incidence of RAS following smoking cessation,9–11 and resolution of lesions upon 
resumption of cigarette smoking.12,13 Although the highest incidence of RAS reported Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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in the literature was found in young adults, particularly 
university students14,15 in whom the habit of smoking is preva-
lent, no studies were conducted on this group to verify this 
commonly held perception of smoking protection from RAS. 
Therefore, this investigation was conducted on a sample of 
university students to study the relationship between smoking 
and RAS among this population.
Methods
The study was conducted as face-to-face interviews with a 
random sample of 1000 students studying at The University 
of Jordan (UJ), Amman, in the period between May and 
September 2008. The students were given sufficient details 
about RAS and were shown pictures of typical cases of the 
condition. They were also shown pictures of recurrent herpes 
labialis in order to avoid mistakes between the two condi-
tions. Students who agreed to participate were subsequently 
asked if they had RAS in the last 12 months. The annual 
prevalence (AP) of the number of students who had positive 
history of RAS in the last 12 months out of the surveyed 
sample was then calculated. The students who had a posi-
tive history of RAS were asked about the annual recurrence 
rate and the number of ulcers and healing period in the last 
episode. Data on demographic characteristics were collected 
for each student. Details of smoking history; method, aver-
age daily dose, and duration of the habit were taken for 
each student. For those who smoked cigarettes, the average 
number of cigarettes smoked throughout life (average of 
daily smoked cigarettes multiplied by duration of habits 
in days) was calculated. Cigarette smokers were classified 
into light smokers (smoking 1–10 cigarettes/day), moderate 
smokers (smoking 11–20 cigarettes/day), and heavy smokers 
(smoking .20 cigarettes/day). While it was simple to record 
the intensity and duration of cigarette smoking, difficulties 
were encountered in knowing the dose or duration of narghile 
smoking because the habit had no constant pattern.
Statistical methods
Statistical analysis was performed using SPSS for Windows 
release 16.0 (SPSS Inc, Chicago, IL). Frequency distribu-
tions were obtained and chi-square test, Student’s t-test, 
and ANOVA test were used to compare differences between 
groups. Statistical significance was set at P , 0.05.
Results
The study population consisted of 1000 students (373 males 
and 627 females). Their ages ranged from 17 to 29 years 
(mean = 20.3 ± 1.79 years). The AP of RAS was 37.1%; 
371 students had RAS episodes in the last 12 months. Of the 
371 subjects, 66.8% had a positive family history of the 
  disease. The relationship of the AP of RAS with the different 
sociodemographic variables is shown in Table 1.
As shown in Table 2, tobacco use was common among 
this group and the prevalence was significantly higher in 
males (P , 0.001, χ2 test). Of the 302 smokers, 18.1% were 
cigarette smokers and 12.1% were narghile smokers. While 
cigarette smoking was prevalent among male students, 
narghile smoking was equally popular among female and 
male students.
The prevalence of RAS was not significantly affected by 
history of tobacco use (Table 1). Although the prevalence 
of RAS was highest among ex-smokers (46.4%), the AP in 
non-smokers (36.7%) was nearly equal to that in smokers 
(37.1%). In addition, the method of tobacco use, cigarettes 
or narghile, had no significant effect on the AP of RAS.
When the group who smoked cigarettes (n = 181) was 
studied separately in terms of AP of RAS, the prevalence 
was significantly affected by number of smoked cigarettes 
each day (Table 3). The prevalence decreased significantly 
as number of daily smoked cigarettes increased (χ2 test; 
P = 0.021); heavy smokers had one-third the odds of RAS 
(odds ratio [OR] = 0.33) than light smokers. In addition, ciga-
rette smokers for periods .5 years also had one-third the odds 
of RAS (OR = 0.34) than those who smoked for #5 years (χ2 
test; P = 0.009). When both these two factors; intensity and 
duration of cigarette smoking, were combined, even moder-
ate cigarette smokers for periods more than five years and 
heavy cigarette smokers for periods less than five years had 
significantly lower risk of getting RAS (χ2 test; P = 0.008). 
The maximum number of cigarettes consumed by moderate 
smokers in 5 years (36,500 cigarettes) was used as a cut-off 
value above which smokers were found to have significantly 
lesser odds (OR = 0.46) of RAS than those who smoked 
below this level (χ2 test; P = 0.042).
However, no significant associations were found between 
the number of the smoked cigarettes per day or duration of 
the habit and the RAS severity in terms of the number of 
ulcers in each episode, duration of the healing period, and 
annual recurrence rate (Table 4). In addition, no significant 
associations were found between RAS severity and total 
number of cigarettes smoked per life.
Discussion
Recurrent aphthous stomatitis was common among the 
investigated population and the AP (37.1%) was significantly 
higher than that (17.9%) reported in US adult population Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
575
Recurrent aphthous stomatitis and smoking
aged over 17 years.8 However, a high prevalence of RAS 
(60%) was reported in US female student nurses.14 Although 
it is expected that young educated people provide rationally 
accurate data regarding RAS, the possibility that the recurrent 
oral ulcerations reported by the investigated population were 
caused by other factors can not be excluded. The results of this 
study revealed also widespread tobacco use among   Jordanian 
university students. Nearly 30% were users of tobacco prod-
ucts and, even in this conservative community, the habit was 
becoming increasingly common among females.
Although better understanding of the relationship between 
smoking and RAS might be important in clarifying the still 
unknown etiology and pathogenesis of RAS, only a few   studies4–13 
were designed specifically to examine this relationship.
The results of this study showed high occurrence of RAS 
in both smokers and nonsmokers. RAS prevalence between 
smokers and nonsmokers was not significantly different. 
Our findings contradict previous studies that found a nega-
tive epidemiological association between tobacco use and 
RAS.4–13 Some of these studies were observational studies 
on three or four patients12,13 or recruited a small number 
of patients with RAS.6,8 Other studies were conducted in 
hospitals or university clinics with a possible selection bias.6,7 
In addition, other studies that found significant relationships 
between smoking and RAS used only bivariate analyses.5–7 
Several variables found to be significant in bivariate analyses 
may turn insignificant in multivariate model. For instance, 
it is well-known that while RAS prevalence decreases with 
Table 1 Demographic variables of students and its relationship with the annual prevalence of RAS
Variables Total Annual prevalence
n %a n %a P valueb
gender Female 
Male
627 
373
62.7 
37.3
239 
132
38.1 
35.4
0.39
Address Amman 
Other regions
797 
203
79.7 
20.3
310 
61
38.9 
30
0.02
Marital status Single 
Married
980 
20
98.0 
2.0
362 
9
36.9 
45
0.46
College health 
Science 
humanitarian
295 
395 
310
29.5 
39.5 
31.0
105 
146 
120
35.6 
37 
38.7
0.73
household income/month ,500 JOD 
$500 JOD
296 
704
29.6 
70.4
114 
257
38.5 
36.5
0.55
Chronic disease Absent 
Present 
  Anemia 
  giT disease 
  Allergies 
  endocrine disorders 
  Others
905 
95 
25 
7 
38 
11 
14
90.5 
9.5 
2.5 
0.7 
3.8 
1.1 
1.4
326 
45 
13 
3 
16 
5 
8
36.0 
47.4 
52 
42.9 
42.1 
45.5 
57.1
0.03
Smoking no 
exsmoker 
narghile smokers 
Cigarette smokers
670 
28 
121 
181
67.0 
2.8 
12.1 
18.1
246 
13 
47 
65
36.7 
46.4 
38.8 
35.9
0.72
Notes: aRaw percentage; bChi-square test.
Abbreviations: giT, gastrointestinal; JOD, Jordanian Dinar (JOD 1 = 1.4$); n, number; RAS, recurrent aphthous stomatitis.
Table 2 Tobacco use among a sample of 1000 male and female students studying at the University of Jordan
Total Smoking history
Nonsmokers Exsmokers Cigarette 
smokers
Narghile 
smokers
n %a n  %a n  %a n  %a n %a
Female 627 62.7 491 78.3 14 2.2 48 7.7 74 11.8
Male 373 37.3 179 48.0 14 3.8 133 35.7 47 12.6
Total 1000 100 670 67.0 28 2.8 181 18.1 121 12.1
Note: aRaw percentage.
Abbreviation: n, number.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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increasing age, smoking prevalence and amount of cigarettes 
consumed usually increase with time. Therefore, it is possible 
that higher mean age of smokers compared to non-smokers 
was responsible for the significantly lower prevalence of 
RAS in smokers reported in some studies that used only 
bivariate analysis. In addition, increase in incidence of RAS 
in those who ceased smoking9–13 is not a proof that smoking 
is responsible since other factors could be involved such as 
increased stress and depression, which usually affect these 
subjects when they stop smoking.16
However, the results of this study did not entirely exclude 
a possible negative epidemiological association between 
smoking and RAS. Significant differences in the prevalence 
of RAS in the group who were cigarette smokers were related 
to the dose and duration of the smoking habit. The “protective 
effect” of tobacco on RAS was only noticed when persons 
were heavy smokers or smoked for longer periods of time. 
Of course this lower prevalence of RAS in the heavy smok-
ers shouldn’t encourage smokers who suffer from RAS to 
increase their consumption.
Data upon the “protective effect” of smoking on RAS 
are controversial particularly with respect to a possible 
underlying mechanism. Some researchers thought that this 
protective effect is related to the increased keratinization 
of the oral mucosa in smokers and that this keratin layer 
acts as a mechanical and chemical barrier against trauma 
or microbes.4,5,10 In contrast, some have hypothesized that 
nicotine may be the responsible agent for the reduction in 
Table 3 Details of cigarette smoking habit in the current smokers (n = 181) and its relationship with the annual prevalence of RAS
Smoking Total Annual prevalence
n %a n  %a Odds ratio 95% CI P valueb
Amount (cigarette/day) 0.021
  Light smoker 52 28.7 23  44.2 1.00
  Moderate smoker 86 47.5 33  38.4 0.79 0.39–1.58
  heavy smoker 43 23.8 9  20.9 0.33 0.13–0.83
Duration (years) 0.009
  #5 139 76.8 57  41 1.00
 . 5 42 23.2 8  19 0.34 0.15–0.79
Amount × duration 0.008
  Light smoker for #5 years 50 27.6 23 46 1.00
  Light smoker for .5 years 2 1.1 0 0 – –
  Moderate smoker for #5 years 67 37 29 43.3 0.90 0.43–1.87
  Moderate smoker for .5 years 19 10.5 4 21.1 0.31 0.09–0.98
  heavy smoker for #5 years 22 12.2 5 22.7 0.35 0.11–0.99
  heavy smoker for .5 years 21 11.6 4 19 0.28 0.08–0.94
Amount (cigarette/life) 0.042
 # 36,500c 127 70.2 52  40.9 1.00
 . 36,500 54 29.8 13  24.1 0.46 0.22–0.94
Notes: aRaw percentage; bChi-square test; cMaximum number of cigarettes consumed by moderate smokers in 5 years. Light smoker (those who smoke 1–10 cigarettes/day); 
moderate smoker (those who smoke 11–20 cigarettes/day); heavy smoker (those who smoke .20 cigarettes/day).
Abbreviations: CI, confidence interval; n, number; RAS, recurrent aphthous stomatitis.
Table 4 Relationship between smoking and severity of RAS in students who were nonsmokers or cigarette smokers and had positive 
history of RAS (n = 311)
Number of ulcers/last episode 
Mean (95% CI)
P valuea Healing 
period/days
P valuea Recurrence rate/year 
Mean (95% CI)
P valuea
Number of cigarettes/day
0 (n = 246) 1.49 (1.37–1.61) 0.52 5.91 (5.45–6.36) 0.77 3.50 (3.14–3.87) 0.12
1–10 (n = 23) 1.39 (1.18–1.61) 5.91 (4.78–7.04) 4.57 (3.05–6.08)
11–20 (n = 33) 1.36 (1.10–1.63) 6.30 (4.34–8.26) 2.79 (1.91–3.66)
.20 (n = 9) 1.11 (0.85–1.37) 7.11 (4.38–9.84) 4.56 (0.62–8.50)
Duration (year)
0 (n = 246) 1.49 (1.37–1.61) 0.29 5.91 (5.45–6.36) 0.70 3.50 (3.14–3.87) 0.84
#5 (n = 57) 1.30 (1.15–1.45) 6.19 (5.01–7.38) 3.60 (2.78–4.41)
.5 (n = 8) 1.62 (0.86–2.39) 6.88 (3.40–10.35) 4.12 (1.00–8.56)
Note: aAnOVA test.
Abbreviations: CI, confidence interval; n, number; RAS, recurrent aphthous stomatitis.Therapeutics and Clinical Risk Management
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RAS prevalence rate in smokers.8 Nicotine has been shown 
to affect the immune response in inflammatory conditions by 
inducing the production of adrenal steroids through the hypo-
thalamus–pituitary–adrenal axis and reducing the production 
of tumor necrosis factor-α (TNF-α) and interleukins 1 and 6 
through its direct effect on macrophages.17
Some investigators support the belief that nicotine may 
act as protector of the oral mucosa in the patients with RAS 
while subjects who quit smoking often complain of RAS 
and resumption of smoking results in the faster resolution of 
RAS.9–11 In addition, those who quit smoking are less likely 
to develop RAS if they use nicotine replacement therapy 
(NRT) as compared to those who do not use NRT.11 Few 
investigators suggested that smokers may be less psychologi-
cally stressed than nonsmokers and that some psychological 
trigger might affect RAS development.1 The association 
found in this study between heavy cigarette smoking and 
less prevalence of RAS even for periods less than five years 
suggests that nicotine may play a role in preventing the occur-
rence of RAS and that this protective effect of nicotine is 
dose dependent. Since the amount of nicotine inhaled with 
tobacco smoke is quite small because most of the substance 
is destroyed by the heat,18 consumption of cigarettes in 
amounts exceeding a packet per day may result in a protec-
tive nicotine dose. Increased keratinization of the mucosa 
and consequently less susceptibility to ulceration could 
explain the finding that moderate smokers for periods more 
than five years had a lower risk of getting RAS; moderate 
smoking had no protective effect on RAS in periods less 
than five years. As shown in this study, smoking of around 
36,500 cigarettes was needed for the formation of a protec-
tive layer of keratin.
Conclusion
The current study acknowledges a “protective effect” of 
smoking on RAS, but only in conditions of high level of 
consumption that result in enough concentration of nicotine 
or long period of consumption to produce a protective layer 
of keratin. However, no significant associations were found 
between intensity and duration of smoking and severity of 
RAS lesions.
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